⌕
Corcept Therapeutics · CORT · Nasdaq
Tenet 54 · Mixed
Compare
$70.07+1.23%At closeTenet 54 · Mixed
$70.07+0.85 (+1.23%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Corcept Therapeutics (CORT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~20.1%/yr (FY21→FY25), net margin 13.1%, and free cash flow (~$141.8M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Returns vs FCF (122%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲12.8%
761.4
FY21→FY25CAGR +20.1%/yr
Net income ($M)▼29.4%
99.7
one-off year: see footnoteCAGR −3.0%/yr
Free cash flow ($M)▼27.7%
141.8
FY21→FY25CAGR −4.1%/yr
Diluted EPS▼33.3%
0.82
buyback-liftedCAGR −2.0%/yr
What the receipts whisper · what a headline number hides
Share count
−4.7%

126.0mn → 120.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$211.0K

−90.3% YoY in FY25 · 0.0% of revenue.

Returns vs FCF
122%

$172.9M returned vs $141.8M of FCF in FY25. The gap comes off the balance sheet (see net cash).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)761.4Revenue−13.0COGS748.4Gross profit−254.9R&D−448.7SG&A44.8Op income54.9Tax & other99.7Net income

13¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 98.6% → 98.3%. Net margin 13.1% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
963,647.0761,407.0675,040.0482,375.0401,858.0365,978.0▲12.8%+20.1%
Cost of revenue
14,097.012,977.010,882.06,481.05,385.05,281.0▲19.3%+25.2%
Gross profit
949,550.0748,430.0664,158.0475,894.0396,473.0360,697.0▲12.7%+20.0%
Research & development
241,720.0254,908.0246,887.0184,353.0130,991.0113,864.0▲3.2%+22.3%
Selling, general & admin
596,920.0448,725.0280,320.0184,259.0152,848.0122,356.0▲60.1%+38.4%
Total operating expenses
838,640.0703,633.0527,207.0368,612.0283,839.0236,220.0▲33.5%+31.4%
Operating incomefeeds ROC rank
110,910.044,797.0136,951.0107,282.0112,634.0124,477.0▼67.3%−22.5%
Other income, net
20,523.021,666.024,542.017,275.03,557.0529.0——
Pretax income
131,433.066,463.0161,493.0124,557.0116,191.0125,006.0▼58.8%−14.6%
Income tax
−30,859.0−33,189.020,284.018,417.014,773.012,494.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
162,292.099,652.0141,209.0106,140.0101,418.0112,512.0▼29.4%−3.0%
Per share
Diluted EPSbuyback-sensitive
1.270.821.230.940.870.89▼33.3%−2.0%
Diluted shares (mn)
123.20119.99113.48111.74115.97125.96▲5.7%−1.2%
Margins
Gross margin96th pct in Healthcare
98.5%98.3%98.4%98.7%98.7%98.6%▼0.1pp−0.3pp
Operating margin
11.5%5.9%20.3%22.2%28.0%34.0%▼14.4pp−28.1pp
Net margin80th pct in Healthcare
16.8%13.1%20.9%22.0%25.2%30.7%▼7.8pp−17.7pp
† TTM = trailing four quarters through 2026-09-30.FY25 effective tax rate was −50% vs a 13% norm for this window, likely a one-time item; see the filing.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Corcept Therapeutics' revenue last fiscal year?

Corcept Therapeutics reported revenue of $761.4M in fiscal 2025, up 12.8% from fiscal 2024.

What was Corcept Therapeutics' net income?

Corcept Therapeutics reported net income of $99.7M in fiscal 2025, a net margin of 13.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.